Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30042504 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3163792 | 0.86 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3151065 | 0.85 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3153465 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1135850 | 0.82 | L3MBTL1 (0.63) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL11033001 | 0.81 | ALDH1A1 (0.80) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1340893 | 0.81 | ALDH1A1 (0.80) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3163262 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL13818364 | 0.80 | P2RY1 (0.57) | P2RY1P2RY14 | |
| SCHEMBL3148533 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KMT2ANPC1RAB9AP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-8053450-B2 | P2Y1 Purinoreceptor; thromboembolic disorders; compounds are 2-((hetero)arylamino) benzimidazoles, benzoxazoles or benzothiazoles such as [2-(2-tert-butyl-phenoxy)-pyridin-3-yl]-(6-methyl-1H-benzoimidazol-2-yl)-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053450-B2 | P2Y1 Purinoreceptor; thromboembolic disorders; compounds are 2-((hetero)arylamino) benzimidazoles, benzoxazoles or benzothiazoles such as [2-(2-tert-butyl-phenoxy)-pyridin-3-yl]-(6-methyl-1H-benzoimidazol-2-yl)-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-08 | — | — | US | disclosed |
| EP-1954696-B1 | 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7714002-B2 | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060293522-A1 | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1706398-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060173002-A1 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-03 | — | — | US | disclosed |
| WO-2006078621-A2 | 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2005113511-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-15 | — | — | US | disclosed |
| WO-2005070920-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293522-A1 | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY13 | ALDH1A1 3230/4885MEN1 1429/4885KMT2A 4010/4885 |
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | P2RY1, P2RY11, P2RY2 | ALDH1A1 1996/4885MEN1 2514/4885KMT2A 3986/4885 |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | P2RY1, P2RY11, P2RY2 | ALDH1A1 2158/4885MEN1 2322/4885KMT2A 4066/4885 |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | ALDH1A1 1978/4885MEN1 3173/4885KMT2A 4568/4885 |
| US-20060173002-A1 | Heteroaryl compounds as P2Y1 receptor inhibitors | P2RY1, P2RY11, P2RY2 | ALDH1A1 2158/4885MEN1 2322/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.